| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-06-23 | Treeway (The Netherlands) Amarna Therapeutics (The Netherlands) | amyotrophic lateral sclerosis | licensing |
Neurodegenerative diseases - Rare diseases | Licensing agreement | |
| 2014-06-23 | Bayer (Germany) Dimension Therapeutics (USA - MA) | adeno-associated virus (AAV) gene therapy | hemophilia A | development commercialisation |
Rare diseases - Genetic diseases - Hematological diseases | Development agreement |
| 2014-06-23 | BioLineRx (Israel) University of Colorado (USA -CO) | BL-1110 | licensing |
CNS diseases - Autoimmune diseases | Licensing agreement | |
| 2014-06-19 | Merrimack Pharmaceuticals (USA -MA) Sanofi (France) | MM-121 | heregulin-positive tumors | licensing |
Cancer - Oncology | Licensing agreement |
| 2014-06-19 | BIND Therapeutics (USA) Roche (Switzerland) | nanomedicines using Accurins | undisclosed | R&D |
undisclosed therapeutics areas outside of oncology | R&D agreement |
| 2014-06-19 | Boehringer Ingelheim (Germany) Evotec (Germany) | R&D - research - development | CNS diseases - Inflammatory diseases - Cardiovascular diseases - Respiratory diseases - Cancer - Oncology | Milestone | ||
| 2014-06-19 | Medical Research Council (MRC), Araclon (Spain), MedImmune, the global biologics research & development arm of AstraZeneca (UK), GSK (UK), IXICO (UK), Janssen Research & Development in collaboration with Johnson & Johnson Innovation (USA), SomaLogic (USA), Cardiff University (UK), University of Cambridge (UK), University of Edinburgh (UK), Imperial College London (UK), Newcastle University (UK), University of Oxford (UK), Swansea University (UK), University College London (UK) | UK Dementias Research Platform (UKDP) | dementias, Alzheimer’s disease, Parkinson’s disease, motor neurone disease | collaboration |
CNS diseases - Mental diseases - Neurogedegenerative diseases | Collaboration agreement |
| 2014-06-19 | Cellmid (Australia) Biotecnol (UK) Rodon Biologics (Portugal) | CAB102 antibody | production manufacturing |
Cancer - Oncology | Production agreement | |
| 2014-06-18 | Cellectis (France) Pfizer (USA - NY) | Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies directed at select targets | Cancer - Oncology | Collaboration agreement | ||
| 2014-06-18 | MRC Technology (UK) Pfizer (USA - NY) | melanocortin receptors (MCRs) programme | Pipeline acquisition | |||
| 2014-06-18 | Recipharm (Sweden) Clinical Trial Consultants - CTC (Sweden) | collaboration clinical research |
Clinical research agreement | |||
| 2014-06-18 | Janssen Pharmaceuticals, a J&J company (USA - NJ) - Vertex Pharmaceuticals (USA - MA) | VX-787 | influenza | development licensing manufacturing production commercialisation |
Infectious diseases | Licensing agreement |
| 2014-06-18 | AstraZeneca (UK) Academic Drug Discovery Consortium - ADDC (USA) | Development agreement | ||||
| 2014-06-17 | Merck KGaA, Merck Serono (Germany) Ono Pharmaceutical (Japan) | ceralifimod (ONO-4641) | multiple sclerosis | licensing
|
Autoimmune diseases - Neurodegenerative diseases | Termination of an agreement |
| 2014-06-17 | Enterome Bioscience (France) Mayo Clinic (USA - MN) | gut microbiome-based diagnostic tests | obesity, overweight | development |
Diagnostic - Metabolic diseases | Development agreement |
| 2014-06-16 | EIB - European Investment Bank (EU) - UCB (Belgium) | selected UCB compounds | collaboration |
Neurological diseases - Immunological diseases | Collaboration agreement | |
| 2014-06-16 | Cardio3 BioSciences (Belgium) Medisun International (China) | C-Cure® | joint-venture |
Cardiovascular diseases | Joint-venture agreement | |
| 2014-06-14 | Sanofi (France) Medtronic (USA -MN) | drug-device combinations and delivery of care management services | type 2 diabetes | collaboration |
Metabolic diseases | Collaboration agreement |
| 2014-06-12 | MorphoSys (Germany) Merck Serono (Germany) | therapeutic antibodies against undisclosed immune checkpoints | R&D |
Cancer - Oncology | R&D agreement | |
| 2014-06-12 | Horizon Discovery (UK) the Broad Institute (UK) | intellectual property related to the CRISPR/Cas9 gene editing system | licensing |
Technology - Services | Licensing agreement |
